Positive preclinical results in Xintela’s glioblastoma project
Lund, Sweden, December 11, 2019 – Xintela AB (publ) announces positive preclinical results in the glioblastoma project. Xintela has developed function-blocking antibodies that bind to the company’s target integrin a10b1 and identified an antibody that suppresses the growth of glioblastoma tumors in a preclinical model. In order to develop targeted antibody-based therapy for the aggressive […]
Xintela publishes interim report for the third quarter
Summary of the interim report The “company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First nine months of the year (1 Jan 2019-30 Sep 2019)· Income amounted to TSEK 3 (1,012).· Loss before tax totalled TSEK -28,081 (-17,581).· Loss per share* was SEK -0.71 (-0.58).· At 30 September 2019, the equity/assets […]
Year-end Report 2018
The aim is set for clinical studies The final quarter of the year was very eventful, and successful in terms of both projects and financing. We conducted a directed share issue of MSEK 50 to the German orthopaedic company Bauerfeind AG. In the companies stem-cell project, our aim is to commence clinical trials in Australia. […]
Xintela Interim Report Q3 2018
XINTELA TO SPIN OUT ONCOLOGY BUSINESS
Lund, Sweden, August 29, 2018 – Xintela AB (publ) announces today that the company has made the decision to spin out its oncology business to a newly formed subsidiary company, Targinta AB. The Xintela Board has decided to move the oncology business into a separate company, with plans to distribute shares to Xintela’s owners and […]
Xintela Interim Report Q2 2018
Xintela signs Letter of Intent with CO.DON
Xintela AB (publ) announces today that the company has signed a Letter of Intent with the leading European cell therapy company CO.DON. The parties intend to co-develop a stem cell product for the treatment of osteoarthritis, based on Xintela’s stem cell technology. CO.DON will pay an exclusivity fee for a 6- month period, during which […]
Xintela receives MUMS-status for the treatment of osteoarthritis in horses
Lund, Sweden, 28th of June 2018 – Xintela announces today that the company has received MUMS-status (Minor Use Minor Species) in Europe for the treatment of degenerative joint disease, including osteoarthritis, in horses. MUMS-status is the veterinary equivalent of Orphan Drug in human medicine. The MUMS classification gives a significant reduction of documentation requirements prior […]
Xintela Interim Report Q1 2018
Xintela prepares for oncology spinout
Xintela AB (publ) announces today that the company has decided to prepare for a possible spin-out of its oncology business into a separate company to be distributed to Xintelas existing shareholders through a stock dividend and listed on a suitable stock market during 2018. Since 2014, Xintela’s cancer project focusing on the aggressive brain tumor […]
